Slap Pharmaceuticals LLC have identified new poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.
Alumis Inc. has patented non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of cancer, neurological, autoimmune, inflammatory and endocrine disorders.
Sparx Group has formed a strategic alliance with Arovella Therapeutics Ltd. for the development of a CLDN18.2-chimeric antigen receptor (CAR)-invariant natural killer T (iNKT) cell therapy.
Research at Prelude Therapeutics Inc. has led to the identification of thaizole-pyrimdiine cyclin-dependent kinase (CDK) inhibitors reported to be useful for the treatment of cancer.
A recent Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. patent describes nitrogen-containing heterocyclic derivatives acting as EGFR (del19 mutant) inhibitors and reported to be useful for the treatment of non-small-cell lung cancer.
Ideaya Biosciences Inc. has announced the selection of a Werner helicase inhibitor development candidate. The candidate is a potent, selective, small-molecule inhibitor of the helicase domain of Werner protein and is being advanced for tumors characterized by high microsatellite instability (MSI-high).
Recurrent driver mutations in FMS-related receptor tyrosine kinase 3 (FLT3) occur in around one-third of patients with de novo acute myeloid leukemia (AML). Although most FLT3 mutations are secondary events in leukemogenesis, they are associated with accelerated clonal expansion and disease progression, and treatment with the tyrosine kinase inhibitor midostaurin has been shown to increase patients’ long-term survival. However, the efficacy of FLT3 inhibitors in eliminating FLT3-mutated clones is variable.
Wigen Biomedicine Technology (Shanghai) Co. Ltd. scientists have developed kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer.
Histone deacetylase 8 (HDAC8) inhibitors have been reported in a Sookmyung Women’s University patent as potentially useful for the treatment of cancer, neurodegeneration, autoimmune disease, fibrosis and inflammatory disorders.
Finding suitable antigens for immunotherapy of myeloid malignancies, particularly acute myeloid leukemia (AML), is an urgent clinical need. Most AML candidate targets, including CD123, are co-expressed by hematopoietic stem and progenitor cells (HSCPs), with the subsequent risk of myelosuppression associated with myeloid cell-targeted chimeric antigen receptor (CAR) T therapy.
RSS
